Emtricitabine is a nucleoside analogue which inhibits the reverse nucleoside transcriptase enzyme. Structurally this antiviral agent is similar to Lamivudine. This agent is effective at targeting HIV and HBV viruses since these viruses replicate in a reverse transcriptase manner. Studies indicate that the structure of Emtricitabine, specifically the unnatural β-L structural configuration produce greater antiviral effects in vitro on HIV and HBV than other antiviral agents. To activate Emtricitabine it needs to undergo multistep intracellular phosphorylation by various cellular kinases. These studies suggest that Emtricitabine competitively inhibits HIV-1 RT (HIV-1 reverse transcriptase) and can cause termination of DNA chain elongation in the virus via incorporation into the viral genome.
1. Darque, A., et al. 1999. Antimicrob. Agents Chemother. 43: 2245-2250. PMID: 10471573
2. Das, K., et al. 2001. J. Virol. 75: 4771-4779. PMID: 11312349
3. Dando, T.M. and Wagstaff, A.J. 2004. Drugs. 64: 2075-82. PMID: 15341498
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.